MIGS is an acronym for Minimally Invasive Glaucoma Surgery. There are various devices used in minimally invasive glaucoma surgery to lower the intraocular pressure and decrease patients’ dependence or need to use eye drops for their glaucoma. These include devices designed to bypass the trabecular meshwork such as the iStent.
iStent® trabecular micro-bypass system is a FDA-approved device that has been developed to address the limitations of current medical and surgical approach for the treatment of glaucoma. The iStent bypasses the trabecular meshwork that may be obstructed and is placed in Schlemm’s canal to potentially improve the outflow of the eye’s natural fluid (aqueous humour) and to lower the pressure inside the eye by creating a permanent opening in the trabecular meshwork. Implantation of this stent into Schlemm’s canal allows aqueous humor to drain directly from the anterior chamber into the canal bypassing the obstructed trabecular meshwork.
The iStent Trabecular Micro-Bypass Stent is indicated for use in conjunction with and after cataract surgery for the control of intraocular pressure in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication.
For more information on this micro invasive glaucoma surgery device please visit http://www.glaukos.com/